Cargando…

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, “standard-of-care” anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Roselli, Mario, Cereda, Vittore, di Bari, Maria Giovanna, Formica, Vincenzo, Spila, Antonella, Jochems, Caroline, Farsaci, Benedetto, Donahue, Renee, Gulley, James L, Schlom, Jeffrey, Guadagni, Fiorella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862634/
https://www.ncbi.nlm.nih.gov/pubmed/24353914
http://dx.doi.org/10.4161/onci.27025
_version_ 1782295765948825600
author Roselli, Mario
Cereda, Vittore
di Bari, Maria Giovanna
Formica, Vincenzo
Spila, Antonella
Jochems, Caroline
Farsaci, Benedetto
Donahue, Renee
Gulley, James L
Schlom, Jeffrey
Guadagni, Fiorella
author_facet Roselli, Mario
Cereda, Vittore
di Bari, Maria Giovanna
Formica, Vincenzo
Spila, Antonella
Jochems, Caroline
Farsaci, Benedetto
Donahue, Renee
Gulley, James L
Schlom, Jeffrey
Guadagni, Fiorella
author_sort Roselli, Mario
collection PubMed
description Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, “standard-of-care” anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated the important role of regulatory T cells (Tregs) in inhibiting immune responses elicited by immunotherapeutic regimens such as those based on anticancer vaccines or checkpoint inhibitors. However, how the number and immunosuppressive function of Tregs change in cancer patients undergoing treatment with non-immune anticancer therapies remains to be precisely elucidated. To determine whether immunostimulatory therapies can be employed successfully in combination with conventional anticancer regimens, we have investigated both the number and function of Tregs obtained from the peripheral blood of carcinoma patients before the initiation and during the course of chemotherapeutic and targeted agent regimens. Our studies show that the treatment of breast cancer patients with tamoxifen plus leuprolide, a gonadotropin releasing hormone agonist, has minimal effects on Tregs, while sunitinib appears to exert differential effects on Tregs among patients with metastatic renal carcinoma. However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to non-small cell lung cancer patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. These studies provide the rationale for the selective use of active immunotherapy regimens in combination with specific standard-of-care therapies to achieve the most beneficial clinical outcome among carcinoma patients.
format Online
Article
Text
id pubmed-3862634
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38626342013-12-18 Effects of conventional therapeutic interventions on the number and function of regulatory T cells Roselli, Mario Cereda, Vittore di Bari, Maria Giovanna Formica, Vincenzo Spila, Antonella Jochems, Caroline Farsaci, Benedetto Donahue, Renee Gulley, James L Schlom, Jeffrey Guadagni, Fiorella Oncoimmunology Original Research Several lines of investigation have revealed the apparent interplay between the immune system of the host and many conventional, “standard-of-care” anticancer therapies, including chemotherapy and small molecule targeted therapeutics. In particular, preclinical and clinical studies have demonstrated the important role of regulatory T cells (Tregs) in inhibiting immune responses elicited by immunotherapeutic regimens such as those based on anticancer vaccines or checkpoint inhibitors. However, how the number and immunosuppressive function of Tregs change in cancer patients undergoing treatment with non-immune anticancer therapies remains to be precisely elucidated. To determine whether immunostimulatory therapies can be employed successfully in combination with conventional anticancer regimens, we have investigated both the number and function of Tregs obtained from the peripheral blood of carcinoma patients before the initiation and during the course of chemotherapeutic and targeted agent regimens. Our studies show that the treatment of breast cancer patients with tamoxifen plus leuprolide, a gonadotropin releasing hormone agonist, has minimal effects on Tregs, while sunitinib appears to exert differential effects on Tregs among patients with metastatic renal carcinoma. However, the administration of docetaxel to patients with metastatic prostate or breast cancer, as well as that of cisplatin plus vinorelbine to non-small cell lung cancer patients, appears to significantly increase the ratio between effector T cells and Tregs and to reduce the immunosuppressive activity of the latter in the majority of patients. These studies provide the rationale for the selective use of active immunotherapy regimens in combination with specific standard-of-care therapies to achieve the most beneficial clinical outcome among carcinoma patients. Landes Bioscience 2013-10-01 2013-11-01 /pmc/articles/PMC3862634/ /pubmed/24353914 http://dx.doi.org/10.4161/onci.27025 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Original Research
Roselli, Mario
Cereda, Vittore
di Bari, Maria Giovanna
Formica, Vincenzo
Spila, Antonella
Jochems, Caroline
Farsaci, Benedetto
Donahue, Renee
Gulley, James L
Schlom, Jeffrey
Guadagni, Fiorella
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
title Effects of conventional therapeutic interventions on the number and function of regulatory T cells
title_full Effects of conventional therapeutic interventions on the number and function of regulatory T cells
title_fullStr Effects of conventional therapeutic interventions on the number and function of regulatory T cells
title_full_unstemmed Effects of conventional therapeutic interventions on the number and function of regulatory T cells
title_short Effects of conventional therapeutic interventions on the number and function of regulatory T cells
title_sort effects of conventional therapeutic interventions on the number and function of regulatory t cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862634/
https://www.ncbi.nlm.nih.gov/pubmed/24353914
http://dx.doi.org/10.4161/onci.27025
work_keys_str_mv AT rosellimario effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT ceredavittore effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT dibarimariagiovanna effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT formicavincenzo effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT spilaantonella effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT jochemscaroline effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT farsacibenedetto effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT donahuerenee effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT gulleyjamesl effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT schlomjeffrey effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells
AT guadagnifiorella effectsofconventionaltherapeuticinterventionsonthenumberandfunctionofregulatorytcells